Tech Company Financing Transactions
Adaptilens Funding Round
Adaptilens closed a $17.5 million Series A funding round on 4/29/2024. Investors included Perceptive Xontogeny Venture Fund and Pillar VC.
Transaction Overview
Company Name
Announced On
4/29/2024
Transaction Type
Venture Equity
Amount
$17,500,000
Round
Series A
Investors
Perceptive Xontogeny Venture Fund (Lead Investor)
Proceeds Purpose
The company intends to use the funds to drive the development of its accommodating intraocular lens (A-IOL), through first-in-human trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
545 Hammond Street, Chestnut Hill
Newton, MA 02467
USA
Newton, MA 02467
USA
Phone
Undisclosed
Website
Email Address
Overview
We're developing an intraocular lens that imitates the human lens so that patients will have near, intermediate, and distance vision without eyeglasses or contact lenses. We recognize that the natural human eye is perfectly designed, and that the best way to improve a patient's life is not to correct their vision but to fully restore it.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Liane Clamen
Chief Executive Officer
Liane Clamen
Chief Information Officer
Brett Thomes
Chief Operating Officer
Daniel Stanley
Browse more venture capital transactions:
Prev: 4/29/2024: Locate Bio venture capital transaction
Next: 4/29/2024: Zeck venture capital transaction
Share this article
About Our VC Transactions Data
We document tech company VC transactions. VC investment data records reported here are derived from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs